Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention

Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy

(2014) A. Kretz-Rommel et al.   JOURNAL OF IMMUNOLOGY

Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions

(2014) K. Nagahara et al.   JOURNAL OF IMMUNOLOGY

B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation

(2012) W. Hobo et al.   JOURNAL OF IMMUNOLOGY

Selective Blockade of Herpesvirus Entry Mediator-B and T Lymphocyte Attenuator Pathway Ameliorates Acute Graft-versus-Host Reaction

(2012) M.-L. del Rio et al.   JOURNAL OF IMMUNOLOGY

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway

(2011) Y. Sakoda et al.   BLOOD

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

CD200 expression in plasma cell myeloma

(2011) Horatiu Olteanu et al.   BRITISH JOURNAL OF HAEMATOLOGY

PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation

(2011) W. J. Norde et al.   CANCER RESEARCH

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

(2011) D. J. Andorsky et al.   CLINICAL CANCER RESEARCH

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

(2011) Ben Youngblood et al.   IMMUNITY

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

(2011) Taku Okazaki et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

(2011) D. B. Flies et al.   JOURNAL OF IMMUNOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

(2011) S J Coles et al.   LEUKEMIA

Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways

(2011) J. Lee et al.   MOLECULAR AND CELLULAR BIOLOGY

PD-L2 is expressed on activated human T cells and regulates their function

(2011) Nassima Messal et al.   MOLECULAR IMMUNOLOGY

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

B- and T-Lymphocyte Attenuator Targeting Protects Against the Acute Phase of Graft Versus Host Reaction by Inhibiting Donor Anti-Host Cytotoxicity

(2011) Maria-Luisa del Rio et al.   TRANSPLANTATION

Emerging Tim-3 functions in antimicrobial and tumor immunity

(2011) Kaori Sakuishi et al.   TRENDS IN IMMUNOLOGY

Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM

(2010) Theresa L. Murphy et al.   Annual Review of Immunology

The inhibition of the T-cell immunoglobulin and mucin domain 3 (Tim3) pathway enhances the efficacy of tumor vaccine

(2010) Mi Jin Lee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells

(2010) W. Hobo et al.   BLOOD

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

(2010) Q. Zhou et al.   BLOOD

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

The Immunosuppressive Surface Ligand CD200 Augments the Metastatic Capacity of Squamous Cell Carcinoma

(2010) Magda Stumpfova et al.   CANCER RESEARCH

PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma

(2010) Lei Ni et al.   IMMUNOLOGY AND CELL BIOLOGY

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1

(2010) M. Ghiotto et al.   INTERNATIONAL IMMUNOLOGY

Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice

(2010) Shoji Asakura et al.   JOURNAL OF CLINICAL INVESTIGATION

Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation

(2010) Barry Flutter et al.   JOURNAL OF CLINICAL INVESTIGATION

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care

(2010) Andrea DeCensi et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression

(2010) Jörn C. Albring et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion

(2010) Xiaoyuan Huang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their Function

(2010) N.-E. Serriari et al.   JOURNAL OF IMMUNOLOGY

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

(2010) Michael Quigley et al.   NATURE MEDICINE

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

(2010) Margaret K. Callahan et al.   SEMINARS IN ONCOLOGY

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression

(2009) S. Mumprecht et al.   BLOOD

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

(2009) L. Zhang et al.   BLOOD

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms

(2009) Jacek Daroszewski et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention

(2009) Daniel E. Kaufmann et al.   JOURNAL OF IMMUNOLOGY

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

T Cell Intrinsic Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding Microenvironment

(2009) T. C. Cheung et al.   JOURNAL OF IMMUNOLOGY

HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation

(2009) M. L. del Rio et al.   JOURNAL OF LEUKOCYTE BIOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator

(2008) Yoshihiro Oya et al.   ARTHRITIS AND RHEUMATISM

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1–IgV

(2008) C. Zhang et al.   CYTOTHERAPY

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

(2008) R. Brad Jones et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

(2008) A Pérez-García et al.   LEUKEMIA

Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade

(2008) Christian P. Pallasch et al.   LEUKEMIA RESEARCH

Enhancing SIV-specific immunity in vivo by PD-1 blockade

(2008) Vijayakumar Velu et al.   NATURE

CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator

(2008) Guifang Cai et al.   NATURE IMMUNOLOGY

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY

Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek

(2008) G. J. Freeman   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE

Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses

(2008) Xin Feng et al.   TRENDS IN IMMUNOLOGY

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes

(2007) Eva S.K. Rijkers et al.   MOLECULAR IMMUNOLOGY